Madrigal Pharmaceuticals Enters into Agreement with CSPC for Oral GLP-1 Agonist
Thursday, July 31, 2025
Madrigal Pharmaceuticals has entered into an exclusive global licensing agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral small molecule GLP-1 receptor agonist derived from orforglipron.
Metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH), is a progressive liver disease that can lead to serious complications such as cirrhosis, liver failure, liver cancer, and premature death. It is currently the primary cause of liver transplantation in women and the second most common reason overall in the United States. In Europe, MASH is the fastest-growing cause of liver transplant procedures.
The compound is currently in the early stages of development, and Madrigal aims to begin clinical trials in the first half of 2026.
The agreement supports Madrigal’s strategy to strengthen its pipeline in metabolic dysfunction-associated steatohepatitis (MASH). The company sees potential in combining SYH2086 with its approved drug, Rezdiffra, to create a once-daily oral treatment that addresses both weight reduction and liver health.
In previous trials, modest weight loss has been shown to improve the antifibrotic effect of Rezdiffra, suggesting that combining the two treatments could enhance outcomes for MASH patients.
CSPC expressed confidence in Madrigal’s ability to advance SYH2086 through development and deliver benefits to patients globally.
Source: madrigalpharma.com
